Trial Profile
A Study of the Safety and Efficacy of Combination Treatment With REP 2139-Ca and Pegasys in Patients With Hepatitis B / Hepatitis D Co-infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 May 2023
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; REP 2139 (Primary)
- Indications Hepatitis B; Hepatitis D
- Focus Adverse reactions; Proof of concept
- Sponsors REPLICor
- 01 May 2023 Results published in the Replicor media release.
- 01 May 2023 According to Replicor media release, company presented updated clinical data from this study in three oral presentations at the 2023 Global Hepatitis Summit held April 24th-28th in Paris France.
- 10 Sep 2020 According to a REPLICor media release, endpoint data from its most recent REP 301/301-LTF and REP 401 studies presented at EASL Digital ILC meeting 2020.